Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Successful treatment with pemetrexed, Carboplatin, and bevacizumab for platinum-resistant adenocarcinoma of the lung.

Wada S, Fujimoto N, Gemba K, Asano M, Fuchimoto Y, Ono K, Ozaki S, Kishimoto T.

Case Rep Oncol Med. 2012;2012:821280. doi: 10.1155/2012/821280. Epub 2012 Jun 20.

2.
3.

Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.

Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P, Dingemans AM, Joerger M, Schellens JH, Vincent A, van Zandwijk N, Groen HJ.

J Clin Oncol. 2009 Apr 20;27(12):2038-45. doi: 10.1200/JCO.2008.19.1650. Epub 2009 Mar 23.

PMID:
19307503
4.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12. Review.

PMID:
12042984
5.

Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab: a quality of life-oriented randomized phase III study in patients with advanced non-squamous non-small-cell lung cancer (ERACLE).

Galetta D, Pisconti S, Cinieri S, Pappagallo GL, Gebbia V, Borsellino N, Maiello E, Rinaldi A, Montrone M, Rizzo P, Marzano N, Sasso N, Febbraro A, Colucci G.

Clin Lung Cancer. 2011 Nov;12(6):402-6. doi: 10.1016/j.cllc.2011.06.006. Epub 2011 Aug 10.

PMID:
21831718
6.

Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation.

Metro G, Chiari R, Mare M, Giannarelli D, Tofanetti FR, Minotti V, Ferraldeschi M, Giuffrida D, Marcomigni L, Bennati C, Fischer MJ, Meacci M, Bellavita R, Pistola L, Ludovini V, Crinò L.

Cancer Chemother Pharmacol. 2011 Dec;68(6):1405-12. doi: 10.1007/s00280-011-1632-x. Epub 2011 Apr 6.

PMID:
21468755
7.

Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.

Socinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A, Blakely J, Serwatowski P, Karaseva NA, Ciuleanu T, Jassem J, Dediu M, Hong S, Visseren-Grul C, Hanauske AR, Obasaju CK, Guba SC, Thatcher N.

J Clin Oncol. 2009 Oct 1;27(28):4787-92. doi: 10.1200/JCO.2009.23.1548. Epub 2009 Aug 31.

PMID:
19720897
8.

A systematic overview of chemotherapy effects in ovarian cancer.

Högberg T, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):340-60. Review.

PMID:
11441940
9.

A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer.

Adachi S, Ogasawara T, Ito K, Koyama M, Nagano T, Suzuki A, Yamada T, Nakata Y, Ozawa M.

Oncol Rep. 2001 Mar-Apr;8(2):285-8.

PMID:
11182041
10.

A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.

Seiwert TY, Connell PP, Mauer AM, Hoffman PC, George CM, Szeto L, Salgia R, Posther KE, Nguyen B, Haraf DJ, Vokes EE.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):515-22.

11.

Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study.

Xu Y, Ma S, Ji Y, Sun X, Jiang H, Chen J, Du X, Zheng Y, Qiu G.

Lung Cancer. 2011 Jun;72(3):327-32. doi: 10.1016/j.lungcan.2010.09.012. Epub 2010 Nov 5.

PMID:
21056507
12.

[Treatment of the unresectable non small cell lung carcinoma].

Spásová I.

Cas Lek Cesk. 2005;144(9):602-12; discussion 612-3. Review. Czech.

PMID:
16193938
13.

Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients.

Specenier PM, Ciuleanu T, Latz JE, Musib LC, Darstein CL, Vermorken JB.

Cancer Chemother Pharmacol. 2009 Jul;64(2):233-41. doi: 10.1007/s00280-008-0853-0. Epub 2008 Nov 15.

PMID:
19011858
14.

[Pemetrexed alone versus pemetrexed combined with oxaliplatin as salvage therapy in stage IV lung adenocarcinoma].

Liu Y, Jiang Y, Gao Z, Wang X, Han B, Jiang L.

Zhongguo Fei Ai Za Zhi. 2011 Sep;14(9):704-9. doi: 10.3779/j.issn.1009-3419.2011.09.01. Chinese.

15.
16.

Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer.

Socinski MA, Weissman C, Hart LL, Beck JT, Choksi JK, Hanson JP, Prager D, Monberg MJ, Ye Z, Obasaju CK.

J Clin Oncol. 2006 Oct 20;24(30):4840-7. Erratum in: J Clin Oncol. 2007 Jan 1;25(1):167.

PMID:
17050869
17.

Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.

Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, Marangolo M, Parra HJ, Santoro A.

J Clin Oncol. 2006 Mar 20;24(9):1443-8.

PMID:
16549838
18.
19.

Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials.

Zinner RG, Novello S, Peng G, Herbst R, Obasaju C, Scagliotti G.

Clin Lung Cancer. 2010 Mar 1;11(2):126-31. doi: 10.3816/CLC.2010.n.017.

PMID:
20199979
20.

Medical therapy of advanced malignant epithelial tumours of the ovary.

Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.

Forum (Genova). 2000 Oct-Dec;10(4):323-32. Review.

PMID:
11535983

Supplemental Content

Support Center